AB10 | 价格

AB10-1mg / 询价

Anti-CD79B Antibody (Polatuzumab Biosimilar)

产品信息(Product Info)
反应种属(Reactivities)

Human

靶点(Target)

CD79B

同型(Isotype)

Human IgG1-Kappa

标记(Conjugation)

Unconjugated

纯化(Purification)

protein A

无菌(Sterility)

0.2 μM filtered

制剂(Formulation)

PBS, 10% glycerol (pH 7.4)

内毒素(Endotoxin)

Less than 1 EU per μg by the LAL method.

稀释缓冲液
(Recommended Dilution Buffer)

PBS (pH 7.4), contains no stabilizers or preservatives.

纯度(Purity)

<p style="line-height: 25px;">> 95% as determined by Bis-Tris PAGE<br />> 95% as determined by HPLC</p>

存储(Storage)

<p style="line-height: 25px;">Valid for 12 months from date of receipt when stored at -80°C.<br />Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.</p>

应用(Applications)

ELISA

产品数据(Assay Data)
Bis-Tris PAGE
Polatuzumab Biosimilar on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
SEC-HPLC
The purity of Polatuzumab Biosimilar is greater than 95% as determined by SEC-HPLC.
ELISA Data
Immobilized Human CD79B, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Polatuzumab Biosimilar with the EC50 of 1.8ng/ml determined by ELISA. (QC Test)
背景(Background)

CD79B (also known as B29, Ig beta and B cell antigen receptor complex-associated protein beta-chain) is a 36-40 kDa member of the Ig-Superfamily. It is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation.

文献(References)

(1) Dornan D , Bennett F , Chen Y , et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma[J]. Blood, 2009, 114(13):2721-2729.